Featured Sessions

Check out this list of hot-topic sessions that will be of interest to the global oncology community. For more information on any session, visit the iPlanner.

Friday Preview: Science and Education Sessions

1:00 PM–3:15 PM
Workshop: Talking with Patients About Risk and Uncertainty
S405

This workshop will focus on helping physicians talk with patients about risk and uncertainty in the context of genomic test results. Attendees will learn specific strategies for explaining risk and uncertainty to patients, partly by having participants identify their own tolerances to risk and uncertainty and recognize how these may influence the way they convey information to patients. The program will include videos of doctors speaking with patients about risk and simulated patient/physician group exercises.

1:00 PM–3:15 PM
Workshop: Genomics for Oncologists 101
S105ab

The goal of this workshop is to help oncology health care providers learn real-world skills related to genomic testing.  Using a case-based, interactive, small-group approach, faculty will assist participants in acquiring an understanding of introductory principles related to genomic assays, interpretation of results and application to patient care. The workshop will also include practical hands-on instruction with the use of online genomics tools. As such, if available, participants should bring a tablet or laptop (preferred).

1:00 PM–5:00 PM
Workshop: Grant Writing
S103

In this three-part workshop, participants will first hear several 15-minute talks on a variety of topics including grant writing pearls, how to work with a statistician, how to choose a mentor, and what to do when your application is rejected. During the second phase, participants will observe a mock grant selection review similar in methodology to the National Institutes of Health and research foundation awards. The third portion of the workshop will be a small-group, roundtable discussion with experienced grant writers where participants can move between tables.

2:45 PM–5:45 PM
On the Shoulders of Giants: Breast Cancer—Where Precision Medicine Began
S100a

This session gives a historical overview of the evolution of precision medicine.  This extended session is part of ASCO’s continuing effort to highlight the importance of providing oncology fellows, early career oncologists, and oncology practitioners with a historical perspective of cancer—this year the focus being precision medicine. As such, the initial design and target audience for this session is the early career oncologist; however, attendance is open to all Annual Meeting attendees.

2:45 PM–5:45 PM
Oral Abstract Sessions

  • Central Nervous System Tumors (S102)
  • Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics (S406)
  • Health Services Research, Clinical Informatics, and Quality of Care (S404)
  • Hematologic Malignancies—Plasma Cell Dyscrasia (E450)

3:45 PM–6:00 PM
Workshop: Developing a Survivorship Clinic
S405

This practical program on how to develop a survivorship clinic.  The workshop will be divided into two halves: participants will learn specifics about how to establish a survivorship program at both the community oncology setting and at an academic setting. The second portion of the workshop will introduce participants to a novel approach developed at the University of Toronto, the BETTER approach, that integrates survivorship care with general preventive care.

Saturday Preview: Science and Education Sessions

8:00 AM–8:45 AM
How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)
S501

The “How to Navigate the Annual Meeting” session is held in the Trainee & Early Career Oncologist Member Lounge and is the only session in the Lounge that is open to non-members. The session covers how to use Annual Meeting-specific technology, such as the iPlanner and the Virtual Meeting, as well as tips and tricks for optimizing your Annual Meeting experience as a trainee or first-time meeting attendee. 

8:00 AM–9:30 AM
Special Clinical Science Symposium - Tumor Genomics: Finding the Target, Hitting the Target
Hall D1

This session is one of the three specially planned Clinical Science Symposia occurring at the Annual Meeting. These special symposia are designed to address novel and important cross-cutting themes to interest a wide audience of attendees. Abstracts selected for inclusion are considered among the highest caliber research to be presented across the meeting.

9:30 AM–12:00 PM
Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture
Hall B1

ASCO is pleased to welcome leadership from the most influential medical organizations in the United States: NCI Director Norman E. Sharpless, MD, and FDA Commissioner Scott Gottlieb, MD will both speak at the opening session. Additionally, listen to the Presidential Address by ASCO leader Bruce E. Johnson, MD, FASCO, as well as a lecture by oncology pioneer Ralph Weichselbaum, recipient of the David A. Karnofsky Memorial Award

12:00 PM–1:00 PM
ASCO Voices
Arie Crown Theater

Experience the inaugural ASCO Voices session. ASCO Voices, an innovative, unopposed session, brings a variety of perspectives on oncology, medicine, and the world – from big ideas to personal passions.

1:15 PM–2:30 PM
Covering Cancer: Perspectives From the Media
Arie Crown Theater

Gain insights from the media in covering cancer. Practice-changing oncology research is covered by countless media outlets across the globe. Learn from those in the media about their approach to cancer coverage and where they see challenges and opportunities.

3:00 PM–4:15 PM
Biden Cancer Initiative Colloquium
S406

The Biden Cancer Colloquia is a new initiative to provide a platform to engage with the scientific, tech, and data communities within cancer, to highlight the immense progress that has been made and to uncover the challenges and barriers that still remain within the cancer system.  This session will focus on data, one of the top priority areas for the Biden Cancer Initiative, and include both Cancer Moonshot updates and a conversation on patient data ownership.

3:00 PM–6:00 PM
Oral Abstract Sessions

  • Developmental Therapeutics—Immunotherapy (Hall B1)
  • Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant (E450)
  • Pediatric Oncology I (S504)

3:00 PM–4:15 PM
Allen S. Lichter Visionary Leader Award and Lecture
S100a

The second annual Allen S. Lichter Visionary Leader Award will be presented to Nancy E. Davidson, MD, FASCO, of the Fred Hutchinson Cancer Research Center, a breast cancer researcher who has published key findings on the role of hormone response and epigenetics and helped guide several important national clinical trials of new therapies for breast cancer.

4:45 PM–6:00 PM
ASCO Book Club: Black Man in a White Coat by Damon Tweedy, MD
S100bc

Join the discussion as Damon Tweedy, MD, author of the New York Times bestseller Black Man in a White Coat, shares insights about race and bias in medicine, health issues in black communities, and his personal life journey.

Sunday Preview: Science and Education Sessions

7:30 AM–9:15 AM
Highlights of the Day Session I
Hall D1

Looking for a high-level recap of the key findings presented in Saturday's Oral Abstract Sessions? Arrive at the convention center early and attend tomorrow’s Highlights of the Day session, where expert discussants will not only summarize top abstracts presented Saturday, but will also place findings into clinical context. Highlights of the Day sessions will also be held on Monday and Tuesday mornings. Tracks discussed today will include:

  • Central Nervous System Tumors
  • Developmental Therapeutics—Immunotherapy
  • Health Services Research
  • Hematologic Malignancies—Leukemia
  • Hematologic Malignancies—Plasma Cell Dyscrasia
  • Dev Therapeutics - Clinical Pharmacology

8:00 AM–9:30 AM
Overcoming Unique Obstacles to Implementing Precision Medicine Trials in the Community Setting
S100bc

Precision medicine shows great promise for effective treatment options for patients, but many community-based sites do not have access to or are reluctant to participate in these trials. Furthermore, they experience unique barriers to participating in precision medicine trials compared to their academic counterparts. This session will provide necessary information about best practices, resources, and tools to encourage community-based sites to participate in these trials and ensure that their patients gain access to these important treatment options.

8:00 AM–11:00 AM
Oral Abstract Sessions

  • Breast Cancer—Metastatic (Hall D2)
  • Pediatric Oncology II (S504)
  • Patient and Survivor Care (S102)
  • Head and Neck Cancer (E451)
  • Genitourinary (Nonprostate) Cancer (Arie Crown Theater)
  • Cancer Prevention, Hereditary Genetics, and Epidemiology (S404)

9:45 AM-11:00 AM
Special Clinical Science Symposium: Compelling Combinations: Raising the Bar With Immunotherapy
Hall D1

This session is one of the three specially planned Clinical Science Symposia occurring at the Annual Meeting. These special symposia are designed to address novel and important cross-cutting themes to interest a wide audience of attendees. Abstracts selected for inclusion are considered among the highest caliber research to be presented across the meeting.

9:45 AM-11:00 AM
ASCO/European CanCer Organiszation (ECCO) Joint Session: Access and Innovation With Multiplex Genomic Testing
S100a

Speakers in this joint session, chaired by leadership from ASCO and ECCO, will examine the use of multiplex testing in the United States and Europe. Discussion topics include reimbursement and payment in the United States and the European patient perspective.

9:45 AM–12:45 PM
Oral Abstract Sessions

  • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (E450)

11:30 AM–1:00 PM
Collecting and Using Real-World Evidence: Supplementing and Perhaps Replacing Clinical Trials (Includes Presentation of Public Service Award)
S100a

This session will examine how real-world data is being used in the patient care setting. Discussion topics include how the registry community and the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute database is enhancing the real-world evidence ecosystem as well as the U.S. Food and Drug Administration's (FDA) evolving efforts to use real-world evidence to inform effectiveness in the pre- and post-approval settings. This session includes presentation of the Public Service Award to Gideon Blumenthal, MD, of the FDA’s Oncology Center for Excellence.

1:00 PM–4:00 PM
Plenary Session Including the Science of Oncology Award and Lecture
Hall B1; Simulcast: Hall D1

Four clinically significant abstracts have been selected for Plenary pre­sentation and discussion. The intersection of cost, value, and quality of life will be carefully considered in the discussion of each.

The Plenary Session also includes the Science of Oncology Lecture by award recipient Douglas R. Lowy, MD, of the National Institutes of Health, who will discuss the prevention of HPV associated cancers by vaccination.

Plenary Abstract Presentations

  • LBA1: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. First Author: Joseph A. Sparano, MD
  • LBA2: Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). First Author: Gianni Bisogno, MD
  • LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.First Author: Arnaud Mejean, MD, PhD
  • LBA4: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. First Author: Gilberto Lopes, MD, MBA

Post-Plenary Discussion Sessions

  • 4:00 PM4:30 PM: Post-Plenary Discussion Session I: Breast Cancer (S100a)
  • 4:30 PM5:00 PM: Post-Plenary Discussion Session II: Rhabdomyosarcoma (S100bc)
  • 5:00 PM5:30 PM: Post-Plenary Discussion Session III: Kidney Cancer (S100a)
  • 5:30 PM6:00 PM: Post-Plenary Discussion Session IV: Lung Cancer (S100bc)

Monday Preview: Science and Education Sessions

7:30 AM–9:15 AM
Highlights of the Day Session II
Hall D1

Looking for a high-level recap of the key findings presented in Sunday's Oral Abstract Sessions? Arrive at the convention center early and attend tomorrow’s Highlights of the Day session, where expert discussants will not only summarize top abstracts presented Sunday but will also place findings into clinical context. Tracks discussed will include:

  • Breast Cancer—Metastatic
  • Genitourinary (Nonprostate) Cancer
  • Head and Neck Cancer
  • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  • Patient and Survivor Care

8:00 AM-9:15 AM
Hepatocellular Carcinoma: A Global Perspective
S406

This session will review the worldwide variations in epidemiology and therapeutic approaches for patients with hepatocellular carcinoma. Presenters will also evaluate the role of viral hepatitis in the development and prevention of the disease.

8:00 AM–11:00 AM
Oral Abstract Sessions

  • Breast Cancer—Local/Regional/Adjuvant (Hall D2)
  • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Hall B1)
  • Melanoma/Skin Cancers (Arie Crown Theater)
  • Sarcoma (S100a)

9:45 AM–10:05 AM
Cancer Care for Displaced Populations: Conflict and Natural Disasters
S504

Conflict and natural disasters shape our global landscape – and their impact on health care is both critically important and uniquely challenging. Join us for this important and timely session to hear about cancer care in response to conflict and natural disasters, and learn about the role of the United Nations, non-governmental organizations, and academic institutions.

9:45 AM –11:15 AM
Special Clinical Science Symposium: The Arrival of Biosimilars
Hall D1

This session is one of the three specially planned Clinical Science Symposia occurring at the Annual Meeting. These special symposia are designed to address novel and important cross-cutting themes to interest a wide audience of attendees. Abstracts selected for inclusion are considered among the highest caliber research to be presented across the meeting.

9:45 AM –11:15 AM
ASCO/American Association for Cancer Research (AACR) Joint Session: GENIE and CancerLinQ—Data In, Data Out
S406

This special joint session, chaired by ASCO and AACR leadership, will examine the challenges of oncology data curation and real-word application. Presenters will draw on their experiences working with ASCO’s CancerLinQ® health information technology platform, aimed at enhancing and improving the understanding and treatment of cancer, and AACR’s Project GENIE, an international data-sharing project that aggregates and links clinical-grade cancer genomic data with clinical outcomes.

11:30 AM–12:45 PM
Molecular Oncology Tumor Board: Synchronous Primary Lung Cancers
E451

Dr. Anthony John Iafrate and experts in medical oncology, surgery, and pathology will review current clinical understanding of synchronous primary lung cancers.

1:15 PM-2:30 PM
The Emergence of Cancer Biosimilars in the United States: A Clinician’s Guide
S406

This session will look at examples of preclinical and clinical development of biosimilars in oncology and review the U.S. regulatory process in place to guide the review of biosimilar applications. Discussion topics will include the important of building a post-market evidence base in the use of biosimilars in treating patients with cancer.

3:00 PM–6:00 PM
Oral Abstract Sessions

  • Gastrointestinal (Noncolorectal) Cancer (Arie Crown Theater)
  • Genitourinary (Prostate) Cancer (Hall D1)
  • Lung Cancer—Non-Small Cell Metastatic (Hall B1)

4:45 PM - 6:00 PM
Challenges Facing Family Caregivers and Emerging Novel Interventions
S504

The role of caregivers in oncology has taken on new importance as cancer care moves into the outpatient and home-based setting. Too often, though, caregivers are overlooked, and the stresses they encounter can have devastating effects on their own lives. Four experts in the field will discuss these issues during the session.

Tuesday Preview: Science and Education Sessions

7:30 AM–9:15 AM
Highlights of the Day Session III
Hall D1

Expert discussants will summarize top abstracts presented on Monday and will place findings into clinical context. Tracks discussed at this session will include:

  • Breast Cancer—Local/Regional/Adjuvant
  • Gastrointestinal (Noncolorectal) Cancer
  • Genitourinary (Prostate) Cancer
  • Lung Cancer-Non-Small Cell Local-Regional/Small Cell
  • Lung Cancer-Non-Small Cell Metastatic
  • Melanoma/Skin Cancers
  • Sarcoma

8:00 AM–11:00 PM
Oral Abstract Sessions

  • Tumor Biology (S406)

9:45 AM–12:45 PM
Oral Abstract Sessions

  • Gastrointestinal (Colorectal) Cancer (Hall D1)
  • Gynecologic Cancer (S100a)

11:30 AM–12:45 PM
Next-Generation Diagnostics Beyond Tissue
S406

This education session promises to provide an in-depth look at the novel innovations in noninvasive cancer molecular diagnostic platforms as well as their potential and challenges.